Slo-Mo anti-neutrophil cytoplasmic antibody-associated renal vasculitis

被引:1
|
作者
Avello, Alejandro [1 ,2 ]
Fernandez-Prado, Raul [1 ,2 ]
Santos-Sanchez-Rey, Begona [1 ,2 ]
Rojas-Rivera, Jorge [1 ,2 ]
Ortiz, Alberto [1 ,2 ]
机构
[1] Univ Autonoma Madrid, Div Nephrol & Hypertens, IIS Fdn Jimenez Diaz, Dept Med,Sch Med, Madrid, Spain
[2] Inst Carlos III FEDER, Red Invest Renal REDINREN, Madrid, Spain
关键词
ANCA; MPO; mycophenolate; outcomes; rapidly progressive glomerulonephritis; rituximab; therapy; vasculitis; ANCA-ASSOCIATED VASCULITIS; RITUXIMAB; CYCLOPHOSPHAMIDE; GLOMERULONEPHRITIS; AZATHIOPRINE; MAINTENANCE; MYCOPHENOLATE;
D O I
10.1093/ckj/sfaa181
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nephrologists are familiar with severe cases of anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) presenting as rapidly progressive glomerulonephritis. However, less is known about AAV with slowly progressive renal involvement. While its existence is acknowledged in textbooks, much remains unknown regarding its relative frequency versus more aggressive cases as well as about the optimal therapeutic approach and response to therapy. Moreover, this uncommon presentation may be underdiagnosed, given the scarce familiarity of physicians. In this issue of Clinical Kidney Journal, Trivioli et al. report the largest series to date and first systematic assessment of patients with AAV and slowly progressive renal involvement, defined as a reduction in estimated glomerular filtration rate (eGFR) of 25-50% in the 6 months prior to diagnosis after excluding secondary causes. Key findings are that slowly progressive AAV may be less common than previously thought, although it still represents the second most common presentation of renal AAV, it usually has a microscopic polyangiitis, anti-myeloperoxidase, mainly renal phenotype in elderly individuals, diagnosis may be late (over one-third of patients had end-stage kidney disease at diagnosis), clearly identifying an unmet need for physician awareness about this presentation, but those not needing renal replacement therapy at diagnosis still responded to immunosuppression.
引用
收藏
页码:18 / 22
页数:5
相关论文
共 50 条
  • [22] Anti-neutrophil cytoplasmic antibody-associated vasculitis with haemolytic uraemic syndrome
    Shukla, Shubham
    Sekar, Aravind
    Naik, Sachin
    Rathi, Manish
    Sharma, Aman
    Nada, Ritambhra
    Sethi, Jasmine
    Bharati, Joyita
    Divyaveer, Smita
    Kohli, Harbir S.
    Ramachandran, Raja
    INTERNAL MEDICINE JOURNAL, 2022, 52 (08) : 1450 - 1451
  • [23] Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
    Zhao, MH
    Chen, M
    Gao, Y
    Wang, HY
    KIDNEY INTERNATIONAL, 2006, 69 (08) : 1477 - 1481
  • [25] Anti-neutrophil cytoplasmic antibody-associated systemic vasculitis: nature or nurture?
    Gatenby, P. A.
    INTERNAL MEDICINE JOURNAL, 2012, 42 (04) : 351 - 359
  • [26] Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis (AAV) Restricted to the Limbs
    Ojima, Yoshie
    Sawada, Kinya
    Fujii, Hiroshi
    Shirai, Tsuyoshi
    Saito, Ayako
    Kagaya, Saeko
    Aoki, Satoshi
    Takeuchi, Yoichi
    Ishii, Tomonori
    Nagasawa, Tasuku
    INTERNAL MEDICINE, 2018, 57 (09) : 1301 - 1308
  • [27] Anti-neutrophil cytoplasmic antibody-associated vasculitis resembling esophageal cancer
    Kurogochi, Takanori
    Mine, Shinji
    Kawachi, Hiroshi
    DIGESTIVE ENDOSCOPY, 2017, 29 (02) : 236 - 237
  • [28] Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes
    Lei Shi
    Rheumatology International, 2017, 37 : 1779 - 1788
  • [29] Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes
    Shi, Lei
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (11) : 1779 - 1788
  • [30] Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis
    Basu, Neil
    McClean, Andrew
    Harper, Lorraine
    Amft, Esther N.
    Dhaun, Neeraj
    Luqmani, Raashid A.
    Little, Mark A.
    Jayne, David R. W.
    Flossmann, Oliver
    McLaren, John
    Kumar, Vinod
    Erwig, Lars P.
    Reid, David M.
    Macfarlane, Gary J.
    Jones, Gareth T.
    RHEUMATOLOGY, 2014, 53 (05) : 953 - 956